Pharma Technology Focus is free for the iPad. Download our app to read the latest issue and browse our back issues for free.
The abuse of prescription painkillers has reached epidemic proportions in the US and the pharma industry is trying to tackle it with a new class of abuse-deterrent opioid drugs. We take a look at pioneering products and the unique ways in which they are being trialled.
We also get an update on the progress of the US Drug Quality and Security Act and its implementation, explore a new class of synthetic compounds known as antimicrobial lipopeptides which could become an alternative to traditional antibiotics, and review the latest asthma treatments in the pipeline.
Moreover, we hear from GlobalData about the potential of Synthetic Biologics’ novel preventative treatment for Clostridium difficile infections, and ask recruitment specialists why UK pharma companies need to attract new STEM talent to remain competitive on an increasingly international market.
In this issue
Time to ActCreated to protect patients from counterfeit and contaminated drugs, the US Drug Quality and Security Act will establish a uniform, national supply chain for pharmaceuticals. Elly Earls finds out more about the act’s requirements and the challenges the industry can expect as it is implemented.Read the article.
Innovations in Asthma TreatmentAsthma therapies represent a highly active area of drug development, with more than 250 products currently in the pipeline. Abi Millar reports on the major areas of research.Read the article.
Finding an AlternativeA new class of synthetic compounds known antimicrobial lipopeptides, or AMLPs, could represent a real alternative to traditional antibiotics. Rod James finds out more.Read the article.
Synthetic Biologics’ Game ChangerGlobalData’s pharmaceutical industry analyst Marc C. Hansel, PhD explains why Synthetic Biologics’ novel approach to preventing Clostridium difficile infections could be a game changer.Read the article.
A Fight on Two FrontsPainkiller misuse has reached epidemic proportions in the US and the pharma sector is responding with new abuse-deterrent opioid products. Chris Lo explores how these new formulations are being developed and tested.Read the article.
Building BridgesMarkus Dehnhardt, PhD, senior toxicology and pharmacovigilance consultant at ProductLife Group , explains why building unity between regulatory affairs and pharmacovigilance makes sense.Read the article.
The Big Jobs RescueWhat can the UK pharma sector do to attract and retain top talent in STEM roles as the industry becomes more international and the STEM skills gap grows? Abi Millar talks to Sue Rossiter or DHR International about challenges in recruitment.Read the article.
Next issue preview
The task of meeting the safety features requirements of the EU Falsified Medicines Directive is daunting, and the details of the proposed legislation are remain unclear. We ask industry experts to round up the key actions required by manufacturers in implementing their serialisation programmes. We also get an update on the implementation of the Identification of Medicinal Products regulations.
A study of the high failure rates of Parkinson’s trials found that patients’ concerns about receiving a placebo is a major barrier to trial recruitment. We look into new efforts to design clinical trails in a way that avoids the traditionally large placebo control group.
Moreover, we ask why flibanserin, the recently FDA approved drug for sexual desire disorder in women, remains controversial; plus we find out how research exploring the link between farm dust and allergic reactions could create a new approach to preventative asthma treatments.
Digital magazine FAQ
You can read Pharma Technology Focus for free on the iPad. Download our app from the App Store to read the latest issue and browse the back issues in our archive. Sign up for a free subscription in the app and never miss a new issue.
You can also continue to read the desktop version for free on our web viewer. (Browser compatibility: The web viewer works in the latest two version of Chrome, Firefox and Safari, as well as in Internet Explorer 9 and 10. Some features may not be compatible with older browser versions.)